right-img

Home | BMO Capital Markets Reaffirms Hold Rating for Kindred Biosciences Inc (KIN)

BMO Capital Markets Reaffirms Hold Rating for Kindred Biosciences Inc (KIN)

May 30, 2017
Kindred Biosciences Inc (NASDAQ:KIN)‘s stock had its “hold” rating reiterated by BMO Capital Markets in a research note issued on Monday, May 15th, StockTargetPrices.com reports. They presently have a $8.00 price objective on the biopharmaceutical company’s stock. BMO Capital Markets’ price target would indicate a potential upside of 11.89% from the stock’s current price. Kindred […]
Read more at:https://www.americanbankingnews.com/2017/05/29/bmo-capital-markets-reaffirms-hold-rating-for-kindred-biosciences-inc-kin.html

Site Created by finaceandbankingnewsnow.com